Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 935-853-6 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
The study was designed to investigate the systemic toxicity and potential adverse effects of the test material on reproduction (including offspring development) and complies with the recommendations of the OECD Guidelines for Testing of Chemicals No. 422 “Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test” (adopted 22 March 1996).
This study was also designed to comply with Commission Regulation (EC) No 440/2008 of 30 May 2008 laying down test methods pursuant to Regulation (EC) No 1907/2006 of the European Parliament and of the Council on the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH).
The oral administration of Reaction mass of bis(epoxyethyl) benzene and (ethylphenyl) oxirane to rats by gavage, at dose levels of 200, 100 and 50 mg/kg/day, resulted in treatment-related effects at 200 and 100 mg/kg/day characterized by hyperkeratosis, ulceration/erosion and inflammation/abscesses of the forestomach resulting from local irritation at the site of contact during gavage dosing . No such effects were detected at 50 mg/kg/day. Other than local irritation in the stomach there was no evidence of toxicity at any treatment level. Based on the data the 'No Observed Effect Level' (NOEL) for local (site of contact) irritation is 50 mg/kg/day and in the absence of any other toxicological effects the the 'No Observed Effect Level' (NOEL) for systemic toxicity was considered to be 200 mg/kg/day.
The submission substance was found to be non-toxic during a 28-day repeat dose oral exposure study in the rat.
Repeat dose studies via the dermal and inhalation routes of exposure were not conducted on the basis of a lack of exposure to the submission substance.
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Dose descriptor:
- NOAEL
- 200 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
Additional information
SUMMARY
Introduction.
The study was designed to investigate the systemic toxicity and potential adverse effects of the test material on reproduction (including offspring development) and complies with the recommendations of the OECD Guidelines for Testing of Chemicals No. 422 “Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test” (adopted 22 March 1996).
This study was also designed to comply with Commission Regulation (EC) No 440/2008 of 30 May 2008 laying down test methods pursuant to Regulation (EC) No 1907/2006 of the European Parliament and of the Council on the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH).
Methods.
The test material was administered by gavage to three groups, each of ten male and ten female Wistar Han™:HsdRccHan™:WIST strain rats, for up to fifty-four consecutive days (including a two week maturation phase, pairing, gestation and early lactation for females), at dose levels of 50, 100 and 200 mg/kg/day. A control group of ten males and ten females was dosed with vehicle alone (Arachis oil BP).
Clinical signs, behavioural assessments, bodyweight development, food and water consumption were monitored during the study. Haematology and blood chemistry were evaluated at termination on five selected males and females from each dose group.
Pairing of animals within each dose group was undertaken on a one male: one female basis within each treatment group on Day 15 of the study, with females subsequently being allowed to litter and rear their offspring to Day 5 of lactation.
During the lactation phase, daily clinical observations were performed on all surviving offspring, together with litter size and offspring weights and assessment of surface righting reflex.
Extensive functional observations were performed on five selected males from each dose group after the completion of the mating phase, and for five selected parental females from each dose group on Day 4 post partum.
Males were terminated on Day 43, followed by the termination of all surviving females and offspring on Day 5post partum. All animals were subjected to a gross necropsy examination and histopathological evaluation of selected tissues was performed.
Results.
Mortality.One female treated with 200 mg/kg/day was found dead on Day 5. There were no further unscheduled deaths during the study.
Clinical Observations.Animals of either sex from all treatment groups showed episodes of increased salivation immediately post or one hour post dosing throughout the treatment period.
Behavioural Assessment.There were no treatment-related changes in the behavioural parameters measured.
Functional Performance Tests.There were no treatment-related changes in functional performance.
Sensory Reactivity Assessments.There were no treatment-related changes in sensory reactivity.
Bodyweight.Animals of either sex treated with 200 mg/kg/day showed actual bodyweight losses during Week 1 of treatment. Males from this treatment group continued to show a reduction in bodyweight gain during Week 2. Females treated with 200 mg/kg/day showed actual bodyweight losses during the first week of treatment.
No such effects were detected in animals of either sex treated with 100 or 50 mg/kg/day.
Food Consumption.No adverse effect on food consumption was detected. Food efficiency was however reduced for males treated with 200 mg/kg/day during the first two weeks of treatment and for females from this treatment group during the first week of treatment.
No such effects in food efficiency were detected in animals of either sex treated with 100 or 50 mg/kg/day.
Water Consumption.No intergroup differences were detected.
Haematology.No toxicologically significant effects were detected in the haematological parameters measured.
Blood Chemistry.No toxicologically significant effects were detected in the blood chemical parameters measured.
Reproductive Performance:
Mating and Fertility.There were no treatment-related effects on mating or conception rates for treated animals.
One female treated with 50 mg/kg/day was found to be non-pregnant. One control and two females treated with 200 mg/kg/day failed to show any positive evidence of mating but subsequently gave birth to live young.
Gestation Length.There were no differences in gestation lengths. The distribution for treated females was comparable to controls.
Litter Responses:
Offspring Litter Size and Viability.Of the litters born, litter size at birth and subsequently on Days 1 and 4post partumwere comparable to controls.
Offspring Growth and Development.Litter weights at Day 4post partumwere reduced in females treated with 200 mg/kg/day.
No such effects were detected in litters from females treated with 100 or 50 mg/kg/day.
Litter observations.No clinically observable signs of toxicity were detected for offspring from all treatment groups.
Organ Weights.No toxicologically significant effects were detected in the organ weights measured.
Necropsy.No toxicologically significant effects were detected.
Histopathology.The following treatment-related effects were detected:
STOMACH:Hyperkeratosis of the forestomach was evident in animals of either sex treated with 200 and 100 mg/kg/day. Ulceration was also noted in one male and two females treated with 200 mg/kg/day. Further changes in the forestomach were identified as erosion in one female treated with 200 or 100 mg/kg/day, abscesses in the muscular layer in one male treated with 200 mg/kg/day and inflammation in the muscular layer in one male treated with 100 mg/kg/day and one female treated with 200 mg/kg/day.
Discussion
The oral administration of Reaction mass of bis(epoxyethyl) benzene and (ethylphenyl) oxirane to rats for a period of forty-two days for males and up to fifty-four days for females (including two weeks pre-mating, gestation and early lactation period) at dose levels of up to 200 mg/kg/day resulted in treatment-related effects at 200 and 100 mg/kg/day.
Clinically observable signs identified as increased salivation were observed during the daily clinical observations in all treatment groups. Treatment related microscopic findings representing a local irritant effect were confined to the stomach at 200 and 100 mg/kg/day and examination revealed hyperkeratosis, ulceration/erosion and inflammation/abscesses of the forestomach. Observations of this nature are commonly observed following the oral administration of an unpalatable or slightly irritant test material formulation. The microscopic gastric changes would support the possibility of irritation but such irritation must have been slight since there were no visible signs of gastric irritancy in these animals at necropsy.
There were no toxicologically significant effects observed during the weekly open field arena observations, the haematological parameters measured or the blood chemical parameters measured. Macroscopic findings or organ weight data did not reveal any effects considered to be attributable to treatment.
No toxicologically significant effects in the reproductive parameters were observed. Excluding the three females treated with 200 mg/kg/day that showed inconclusive individual isolated effects, treated and control females showed comparable number of litters at termination on Day 5 post partumand no treatment-related effects were observed for offspring growth or development.
This study was ranked as Relaibility 1 according to the Klimisch et al scale, as it was conducted in compliance with agreed protocols, with no or minor deviations from standard test guidelines and/or minor methodological deficiencies, which do not affect the quality of relevant results.
A repeat dose dermal toxicity study was not conducted on the submisson substance as dermal contact during formulation and use is unlikely, and physicochemical and toxicological properties do not suggest a significant rate of absorption through the skin.
Testing by the inhalation route of exposure is considered in appropriate as exposure to humans via inhalation is considered unlikely, as there is no possibility of exposure to aerosols, particles or droplets of an inhalable size.
Conclusion
The oral administration of Reaction mass of bis(epoxyethyl) benzene and (ethylphenyl) oxirane to rats by gavage, at dose levels of 200, 100 and 50 mg/kg/day, resulted in treatment-related effects at 200 and 100 mg/kg/day characterized by hyperkeratosis, ulceration/erosion and inflammation/abscesses of the forestomach resulting from local irritation at the site of contact during gavage dosing . No such effects were detected at 50 mg/kg/day. Other than local irritation in the stomach there was no evidence of toxicity at any treatment level. Based on the data the 'No Observed Effect Level' (NOEL) for local (site of contact) irritation is 50 mg/kg/day and in the absence of any other toxicological effects the the 'No Observed Effect Level' (NOEL) for systemic toxicity was considered to be 200 mg/kg/day.
Justification for classification or non-classification
The submission substance did not meet the criteria for classification as toxic or harmful by the oral route of exposure during a 28 -day repeat dose toxicity study in the rat.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.